CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Rivastigmine

Last Updated: December 21, 2007
Result type: Reports
Project Number: S0123
Product Line: Reimbursement Review

Generic Name: Rivastigmine

Brand Name: Exelon Patch

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Indications: Dementia (Alzheimer's type)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: July 23, 2008

Recommendation Type: Do not list